

November 25, 2015

Dear Manufacturers,

I am writing on behalf of Albert Einstein Medical Center (Einstein) (340B ID #DSH390142) to inform manufacturers that Einstein recently underwent an audit by the Health Resources and Services Administration (HRSA) of Einstein's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, Einstein qualified for the 340B Program as a disproportionate share hospital in Philadelphia, Pennsylvania and has participated in the 340B Program since January 1, 2005.

Through the audit process, HRSA found Einstein to have non-compliance within its 340B Program and responsible for repayment as a result of the following finding:

1. Einstein dispensed a 340B drug to an ineligible individual, as prohibited by 42 U.S.C. 256b(a)(5)(B).

Einstein has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from Einstein and believe repayment may be owed for the violation described in this letter, or if you have any questions or comments regarding the violation described in this letter please contact Deborah Hauser, Network Director of Pharmacy, 215-456-6486, Albert Einstein Medical Center, 5501 Old York Road, Philadelphia, PA 19141.

Sincerely,

Gerard Blaney  
Vice President Finance  
Albert Einstein Medical Center